Quantitative proteomics identifies tumour matrisome signatures in patients with non-small cell lung cancer.
ADAMTS16
lung
lysine hydroxylation
mass spectrometry
matrisome
non-small cell lung cancer
peroxidasin
proteomic
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2023
2023
Historique:
received:
27
03
2023
accepted:
30
05
2023
medline:
3
7
2023
pubmed:
3
7
2023
entrez:
3
7
2023
Statut:
epublish
Résumé
The composition and remodelling of the extracellular matrix (ECM) are important factors in the development and progression of cancers, and the ECM is implicated in promoting tumour growth and restricting anti-tumour therapies through multiple mechanisms. The characterisation of differences in ECM composition between normal and diseased tissues may aid in identifying novel diagnostic markers, prognostic indicators and therapeutic targets for drug development. Using tissue from non-small cell lung cancer (NSCLC) patients undergoing curative intent surgery, we characterised quantitative tumour-specific ECM proteome signatures by mass spectrometry. We identified 161 matrisome proteins differentially regulated between tumour tissue and nearby non-malignant lung tissue, and we defined a collagen hydroxylation functional protein network that is enriched in the lung tumour microenvironment. We validated two novel putative extracellular markers of NSCLC, the collagen cross-linking enzyme peroxidasin and a disintegrin and metalloproteinase with thrombospondin motifs 16 (ADAMTS16), for discrimination of malignant and non-malignant lung tissue. These proteins were up-regulated in lung tumour samples, and high These data chart extensive remodelling of the lung extracellular niche and reveal tumour matrisome signatures in human NSCLC.
Identifiants
pubmed: 37397358
doi: 10.3389/fonc.2023.1194515
pmc: PMC10313119
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1194515Subventions
Organisme : Wellcome Trust
Pays : United Kingdom
Informations de copyright
Copyright © 2023 Titmarsh, von Kriegsheim, Wills, O’Connor, Dhaliwal, Frame, Pattle, Dorward, Byron and Akram.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Clin Cancer Res. 2005 Feb 1;11(3):1086-92
pubmed: 15709175
Mol Cell Proteomics. 2018 Jul;17(7):1410-1425
pubmed: 29669734
Cold Spring Harb Perspect Biol. 2011 Dec 01;3(12):
pubmed: 21917992
Int J Mol Sci. 2021 Mar 05;22(5):
pubmed: 33807717
Nucleic Acids Res. 2019 Jan 8;47(D1):D506-D515
pubmed: 30395287
Genome Res. 2003 Nov;13(11):2498-504
pubmed: 14597658
Sci Rep. 2021 Nov 3;11(1):21549
pubmed: 34732773
Nat Protoc. 2016 Dec;11(12):2301-2319
pubmed: 27809316
Mol Cell Proteomics. 2012 Oct;11(10):916-32
pubmed: 22761400
Nucleic Acids Res. 2022 Jul 5;50(W1):W216-W221
pubmed: 35325185
Matrix Biol. 2017 Jan;57-58:12-28
pubmed: 27553508
BMC Cancer. 2018 Aug 6;18(1):796
pubmed: 30081852
Mol Cell Proteomics. 2012 Jun;11(6):M111.013946
pubmed: 22298307
Matrix Biol Plus. 2019 Apr 13;1:100005
pubmed: 33543004
Bioinformatics. 2004 Jun 12;20(9):1453-4
pubmed: 14871861
J Biol Chem. 2016 Dec 9;291(50):25799-25808
pubmed: 27803159
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Mol Syst Biol. 2015 Jul 14;11(7):819
pubmed: 26174933
Free Radic Biol Med. 2015 Jun;83:273-82
pubmed: 25708780
Subcell Biochem. 2017;82:457-490
pubmed: 28101870
J Pathol. 2016 Dec;240(4):397-409
pubmed: 27623753
Int J Exp Pathol. 2013 Apr;94(2):75-92
pubmed: 23419153
Nat Commun. 2020 Sep 9;11(1):4520
pubmed: 32908154
Clin Proteomics. 2019 Feb 06;16:6
pubmed: 30774578
Elife. 2022 Apr 19;11:
pubmed: 35437145
Proc Natl Acad Sci U S A. 2017 Jul 11;114(28):E5625-E5634
pubmed: 28652369
Bioinformatics. 2010 Nov 15;26(22):2927-8
pubmed: 20926419
Nat Chem Biol. 2012 Sep;8(9):784-90
pubmed: 22842973
Mol Cell Proteomics. 2016 Jul;15(7):2396-410
pubmed: 27161446
Chest. 2017 Jan;151(1):193-203
pubmed: 27780786
Bioinformatics. 2004 Nov 22;20(17):3246-8
pubmed: 15180930
Essays Biochem. 2019 Sep 13;63(3):417-432
pubmed: 31462529
Elife. 2018 Jul 03;7:
pubmed: 29966587
J Clin Invest. 2015 Mar 2;125(3):1147-62
pubmed: 25664850
Matrix Biol. 2019 Jan;75-76:141-159
pubmed: 29409929
J Am Soc Nephrol. 2014 May;25(5):939-51
pubmed: 24436468
Eur Respir J. 2018 Jul 4;52(1):
pubmed: 29794131
Mol Cell Proteomics. 2021;20:100015
pubmed: 33508502
Matrix Biol. 2018 Oct;71-72:10-27
pubmed: 29730502
Elife. 2022 Feb 21;11:
pubmed: 35188460
Nature. 2013 Sep 19;501(7467):355-64
pubmed: 24048068
Science. 2009 Nov 27;326(5957):1216-9
pubmed: 19965464
Mol Cell Proteomics. 2014 Sep;13(9):2513-26
pubmed: 24942700
J Cell Sci. 2010 Dec 15;123(Pt 24):4195-200
pubmed: 21123617
Matrix Biol. 2016 Jan;49:10-24
pubmed: 26163349
Respir Res. 2015 Jun 24;16:74
pubmed: 26104294
Tumour Biol. 2014 Oct;35(10):9815-21
pubmed: 24986569
Nucleic Acids Res. 2019 Jan 8;47(D1):D330-D338
pubmed: 30395331
Mass Spectrom Rev. 2013 Mar-Apr;32(2):129-42
pubmed: 22829143
Nat Commun. 2018 Nov 8;9(1):4692
pubmed: 30410077
Cold Spring Harb Perspect Biol. 2012 Jan 01;4(1):a004903
pubmed: 21937732
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Nat Methods. 2016 Sep;13(9):731-40
pubmed: 27348712
Cancer Res. 2009 Sep 15;69(18):7252-61
pubmed: 19706765
Oncotarget. 2016 Mar 22;7(12):14857-70
pubmed: 26930711
Expert Rev Proteomics. 2020 May;17(5):377-391
pubmed: 32552150
Nucleic Acids Res. 2020 Jan 8;48(D1):D1136-D1144
pubmed: 31586405
Int J Exp Pathol. 2018 Apr;99(2):58-76
pubmed: 29671911
Nat Rev Cancer. 2012 Apr 19;12(5):323-34
pubmed: 22513401
Anal Chem. 2003 Feb 1;75(3):663-70
pubmed: 12585499
EMBO Rep. 2014 Dec;15(12):1243-53
pubmed: 25381661
Curr Opin Chem Biol. 2008 Feb;12(1):72-7
pubmed: 18295612
J Med Internet Res. 2021 Jul 26;23(7):e27633
pubmed: 34309564
Clin Cancer Res. 2000 Oct;6(10):3944-8
pubmed: 11051242
Expert Rev Proteomics. 2018 Feb;15(2):105-112
pubmed: 29285949